Cargando…
THU508 Does Mid-treatment Response To 177Lu-DOTATATE Predict Treatment Outcome In Patients With Neuroendocrine Neoplasms?
Disclosure: R. Halperin: None. A. Tirosh: None. Introduction - Patients with advanced or unresectable neuroendocrine neoplasm (NENs) have limited systemic treatment modalities. Among these, patients with well differentiated (G1 and G2) NENs can be treated with peptide receptor radionuclide therapy (...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553474/ http://dx.doi.org/10.1210/jendso/bvad114.2136 |